Page 360 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

334 Vanessa Quick and John Kirwan

[153] Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized,
placebo-controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).
Clin. Exp. Rheumatol., 2001; 19:495-501.

[154] Nordborg E, Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment.
Curr. Opin. Rheumatol., 2004; 16:25-30.

[155] Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II.
Relation between steroid dosing and steroid associated side effects. Ann. Rheum. Dis.,
1989; 48:662-666.

[156] Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and
mortality in temporal arteritis: a 15-year survey of 43 patients. J. Rheumatol., 1994;
21:1283–1286.

[157] Adizie T, Christidis D, Dharmapaliah C, et al. Efficacy and tolerability of leflunomide
in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int. J.
Clin. Pract., 2012; 66:906-909.

[158] Sciascia S, Piras D, Baldovino S, et al. Mycophenolate mofetil as steroid-sparing
treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin.
Exp. Res., 2012; 24:273-7.

[159] Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the
treatment of giant cell arteritis. Rheumatology, 2012; 51:1677-1686.

[160] Schaufelberger C, Mollby H, Uddhammar A, et al. No additional steroid-sparing effect
of cyclosporine A in giant cell arteritis. Scand. J. Rheumatol., 2006; 55:327-329.

[161] Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of
glucocorticosteroid-induced remission of giant cell arteritis. Ann. Intern. Med., 2007;
146:621-30.

[162] Salvarani C, Macchioni PL, Manzini C, et al. Infliximab plus prednisone or placebo
plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.
Ann. Intern. Med., 2007; 146:631-639.

[163] Martinez-Taboada V, Rodriguez-Valverde V, Carreno L, et al. A double-blind placebo
controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side
effects Ann. Rheum. Dis., 2008; 67: 625-630.

[164] Vinit J, Bielefeld P, Muller G, Besancenot J. Efficacy of tocilizumab in refractory giant
cell arteritis. Joint Bone Spine, 2012; 79:317-318.

[165] Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment
for 2 patients with giant cell arteritis. J. Rheumatol., 2011; 38:2080-2081.

[166] Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel
vasculitis by IL-6 blockade. A case series. Swiss Med. Wkly, 2011; 141:w13156.

[167] Beyer C, Axmann R, Sahinbegovic E, et al. Anti-interleukin 6 receptor therapy as
rescue treatment for giant cell arteritis. Ann. Rheum. Dis., 2011; 70:1874-1875.

[168] Unizony SH, Dasgupta B, Fisheleva E, et al. Design of the tocilizumab in giant cell
arteritis trial. Int. J. Rheumatol., 2013:912562.

[169] Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in
giant cell arteritis. Medicine, 2004; 83:114–122.

[170] Lee MS, Smith SD, Galor A, et al. Antiplatelet and anticoagulant therapy in patients
with giant cell arteritis. Arthritis Rheum., 2006; 54:3306-3309.

Complimentary Contributor Copy